Iovance Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Iovance Biotherapeutics's earnings have been declining at an average annual rate of -16.5%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 105.4% per year.
Key information
-16.5%
Earnings growth rate
-2.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 105.4% |
Return on equity | -53.0% |
Net Margin | -451.3% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Jan 11Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't
Dec 17Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Nov 11Iovance Biotherapeutics: Moving To The Next Phase
Oct 03Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Sep 06Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Aug 11Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Aug 11Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jun 26Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Aug 04Iovance: TIL Cell Therapy Set To Prove Itself
Jul 11Iovance: Onward To Approval
Apr 20Revenue & Expenses Breakdown
How Iovance Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 91 | -410 | 140 | 298 |
30 Jun 24 | 33 | -440 | 128 | 317 |
31 Mar 24 | 2 | -450 | 110 | 341 |
31 Dec 23 | 1 | -444 | 107 | 344 |
30 Sep 23 | 1 | -433 | 103 | 337 |
30 Jun 23 | 0 | -419 | 104 | 322 |
31 Mar 23 | 0 | -412 | 109 | 309 |
31 Dec 22 | 0 | -396 | 104 | 295 |
30 Sep 22 | 0 | -390 | 101 | 290 |
30 Jun 22 | 0 | -376 | 94 | 283 |
31 Mar 22 | 0 | -358 | 87 | 271 |
31 Dec 21 | 0 | -342 | 84 | 259 |
30 Sep 21 | 0 | -311 | 76 | 236 |
30 Jun 21 | 0 | -284 | 71 | 214 |
31 Mar 21 | 0 | -265 | 66 | 201 |
31 Dec 20 | 0 | -260 | 60 | 202 |
30 Sep 20 | 0 | -255 | 55 | 204 |
30 Jun 20 | 0 | -246 | 49 | 202 |
31 Mar 20 | 0 | -230 | 46 | 192 |
31 Dec 19 | 0 | -198 | 41 | 166 |
30 Sep 19 | 0 | -167 | 38 | 139 |
30 Jun 19 | 0 | -151 | 35 | 126 |
31 Mar 19 | 0 | -134 | 31 | 111 |
31 Dec 18 | 0 | -124 | 28 | 100 |
30 Sep 18 | 0 | -117 | 26 | 93 |
30 Jun 18 | 0 | -105 | 25 | 82 |
31 Mar 18 | 0 | -98 | 23 | 76 |
31 Dec 17 | 0 | -92 | 21 | 72 |
30 Sep 17 | 0 | -82 | 13 | 61 |
30 Jun 17 | 0 | -128 | 17 | 53 |
31 Mar 17 | 0 | -116 | 20 | 38 |
31 Dec 16 | 0 | -102 | 17 | 27 |
30 Sep 16 | 0 | -95 | 25 | 21 |
30 Jun 16 | 0 | -34 | 18 | 17 |
31 Mar 16 | 0 | -29 | 12 | 17 |
31 Dec 15 | 0 | -28 | 12 | 15 |
30 Sep 15 | 0 | -24 | 10 | 14 |
30 Jun 15 | 0 | -19 | 10 | 9 |
31 Mar 15 | 0 | -15 | 9 | 6 |
31 Dec 14 | 0 | -12 | 8 | 4 |
30 Sep 14 | 0 | -27 | 7 | 2 |
30 Jun 14 | 0 | -34 | 7 | 2 |
Quality Earnings: IOVA is currently unprofitable.
Growing Profit Margin: IOVA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IOVA is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare IOVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IOVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (23.5%).
Return on Equity
High ROE: IOVA has a negative Return on Equity (-53.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/07 14:56 |
End of Day Share Price | 2025/02/07 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Iovance Biotherapeutics, Inc. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Colleen Kusy | Baird |
Madhu Kumar | Baird |
Peter Lawson | Barclays |